An Official Website of the United States Government
Company Information:
Name:
ARIDIS PHARMACEUTICALS, LLC
Address:
5941 Optical Court
SAN JOSE, CA
SAN JOSE, CA
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Live, oral, heat Stable S. typhi TY21a vaccine
Award Year / Program / Phase:
2005 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Eric Patzer
Award Amount:
$974,606.00
Abstract:
DESCRIPTION (provided by applicant):
Vaccines represent a proven and effective approach for assuring widespread protection of large populations and can be used to reduce the number of susceptible individuals prior to or immediately following a bioterrorism attack. This project addresses two… More
Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis
Award Year / Program / Phase:
2007 / STTR / Phase I
Agency:
HHS
Research Institution:
BRIGHAM AND WOMEN'S HOSPITAL
Abstract:
DESCRIPTION (provided by applicant): Cystic Fibrosis (CF) is an autosomal recessive disorder, which leads to the abnormal composition and physical properties of airway secretions in CF patients. Additionally, the lungs of CF patients are particularly susce
ptible to chronic bacterial infections with… More
Inhalable Gallium Nitrate Anti-Infective Powder for CF
Award Year / Program / Phase:
2009 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
David Lechugaballesteros
Award Amount:
$599,829.00
Abstract:
DESCRIPTION (provided by applicant): Cystic Fibrosis (CF) is an autosomal recessive disorder, which leads to the abnormal composition and physical properties of airway secretions in CF patients. Additionally, the lungs of CF patients are particularly susce
ptible to chronic bacterial infections with… More
Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis
Award Year / Program / Phase:
2011 / STTR / Phase II
Agency:
HHS
Research Institution:
WAISMAN BIOMANUFACTURING FACILITY, UNIVERSITY OF WISCONSIN
Abstract:
DESCRIPTION (provided by applicant): Over the past two decades, the number of new antimicrobials being developed has experienced a greater than 60% decline, while the number of antibiotic resistant microorganisms has been steadily increasing. Only one newantibacterial drug with a novel mechanism of… More